Porphysome nanoparticles for imaging advanced gynecological cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This early-phase trial tests a new imaging agent called Porphysome nanoparticles to see if it can help doctors see gynecological cancers more clearly on scans. It's for women with advanced cancer that cannot be cured, and who are already receiving standard treatments like chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- Your cancer is advanced (has spread) and is a type of gynecological cancer, like ovarian, uterine, or cervical cancer.
- You are not receiving treatment meant to cure your cancer—only treatments to control it.
- You can lie still for at least 20 minutes and are not claustrophobic.
- You have not had a nuclear medicine scan (like a PET scan) for other reasons during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
This pilot study uses a special PET/CT scan (with a radioactive tracer) to help doctors better “stage” high-grade epithelial ovarian cancer—especially when it’s advanced. The goal is to see whether the scan can improve planning for treatment like surgery or chemotherapy first.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This study tests whether a new imaging agent, MNPR-101-DFO*-89Zr, can find solid tumors and measure their uPAR levels. It might help doctors better understand your cancer and guide future treatment decisions.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Hear when a new Gynecological Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.